Evidence map›Paper›PMID 42828100›Full record

ArticleOncology letters2026

Clinicopathological role of microRNA-205, microRNA-223 and microRNA-590 in vulvar cancer.

Edyta Leśniak, Emilia Stec-Martyna, Bartłomiej Tomasik, Hanna Romanowicz, Oliwia Maciejewska, Jan Bieńkiewicz, Andrzej Malinowski, Miłosz Wilczyński

Abstract read
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Edyta LeśniakDepartment of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
Emilia Stec-MartynaResearch Laboratory CoreLab, Medical University of Lodz, 92-215 Lodz, Poland.
Bartłomiej TomasikDepartment of Oncology and Radiotherapy, Medical University of Gdansk, Faculty of Medicine, 80-214 Gdansk, Poland.
Hanna RomanowiczDepartment of Clinical Pathology, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
Oliwia MaciejewskaDepartment of Operative and Endoscopic Gynecology, Medical University of Lodz, 93-338 Lodz, Poland.
Jan BieńkiewiczDepartment of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
Andrzej MalinowskiDepartment of Operative and Endoscopic Gynecology, Medical University of Lodz, 93-338 Lodz, Poland.
Miłosz WilczyńskiDepartment of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vulvar cancer is a rare malignancy whose development involves environmental, immunologic, genetic and viral factors, including high-risk HPV infection. MicroRNAs (miRNAs/miRs) regulate key oncogenic pathways and may serve as biomarkers in gynecological cancers. However, limited data are available on the role of miR-205, miR-223 and miR-590 in vulvar carcinoma. The present study thus assessed their expression and clinical relevance. A total of 38 women with vulvar carcinoma were included in the study. miRNA expression was quantified using reverse transcription-quantitative PCR from formalin-fixed paraffin-embedded surgical specimens. Among the enrolled patients, 25 had both tumor tissue and matched non-malignant vulvar tissue available for analysis, enabling paired comparisons and fold-change calculations, whereas 13 patients contributed tumor tissue only due to insufficient RNA yield from the matched non-malignant specimen. Statistical analyses included paired t-tests and Kaplan-Meier survival analysis. Clinicopathological features were evaluated using International Federation of Gynecology and Obstetrics (FIGO) staging and histological grading. The results revealed that miR-205 expression was higher in patients with advanced disease, with a significant difference observed between FIGO I-III and FIGO IV tumors. miR-223 expression exhibited a tendency toward an association with poorer tumor differentiation, suggesting its potential as an unfavorable prognostic indicator. miR-590 expression was associated with tumor grade, with higher levels detected in well-differentiated lesions; additionally, the absence of miR-590 expression was linked to a lower likelihood of malignancy, supporting its diagnostic value. A reduced expression of miR-223 was independently associated with an improved overall survival (log-rank, P=0.013). No significant associations between miR-205 or miR-590 and overall survival were identified. On the whole, the present study demonstrated that miR-205, miR-223 and miR-590 expression patterns are associated with the tumor stage, grading and survival outcomes of patients with vulvar cancer. These miRNAs may thus serve as diagnostic or prognostic biomarkers, with miR-223 exhibiting the strongest prognostic significance and miR-590 demonstrating diagnostic specificity. Due to the rarity of vulvar cancer, larger multicenter studies and international datasets are required to validate these findings and to further elucidate the biological roles of miRNAs in this malignancy.

Indexed as

biomarkerFIGO stagegene expressionmicroRNAmiR-205miR-223miR-590prognosistumor gradingvulvar cancer

Identifiers

PMID42828100
PMCPMC13631635

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.